Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3-Amino-2,2-dimethylpropionamide is an organic compound characterized by its white solid appearance. It is a reagent primarily utilized in the synthesis of Aliskiren, a pharmaceutical agent.

324763-51-1

Post Buying Request

324763-51-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

324763-51-1 Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-2,2-dimethylpropionamide is used as a reagent for the synthesis of Aliskiren, a medication that serves as a direct renin inhibitor. This application is crucial in the development of treatments for hypertension and other cardiovascular conditions, as Aliskiren helps regulate blood pressure by inhibiting the renin-angiotensin system.

Check Digit Verification of cas no

The CAS Registry Mumber 324763-51-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,4,7,6 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 324763-51:
(8*3)+(7*2)+(6*4)+(5*7)+(4*6)+(3*3)+(2*5)+(1*1)=141
141 % 10 = 1
So 324763-51-1 is a valid CAS Registry Number.
InChI:InChI=1/C5H12N2O/c1-5(2,3-6)4(7)8/h3,6H2,1-2H3,(H2,7,8)

324763-51-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-Amino-2,2-dimethylpropanamide

1.2 Other means of identification

Product number -
Other names 3-Amino-2,2-dimethylpropionamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:324763-51-1 SDS

324763-51-1Synthetic route

3-Chloropivaloyl chloride
4300-97-4

3-Chloropivaloyl chloride

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonia / dichloromethane / 2.75 h / 20 °C / Cooling with ice
2: sodium methylate; ammonia / methanol / 50 h / 60 °C / Autoclave
View Scheme
Multi-step reaction with 4 steps
1.1: ammonia / dichloromethane / 2.75 h / 20 °C / Cooling with ice
2.1: sodium hydroxide / methanol / 70 h / 50 - 53 °C / Sealed tube
2.2: 0.17 h / 0 - 20 °C
3.1: hydrogenchloride / 20 h / 20 °C
4.1: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
3-bromo-2,2-dimethylpropionic acid
2843-17-6

3-bromo-2,2-dimethylpropionic acid

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ammonia / 1,4-dioxane / 16 h / 60 °C / 2250.23 Torr / Autoclave
2: hydrogenchloride / 20 h / 20 °C
3: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

acetic acid (1S,2S,4S)-2-azido-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester

acetic acid (1S,2S,4S)-2-azido-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 90℃; for 16h; After distillation of a part of Et3N over a period of 0.5 h further 8.5 h heating at 90 °ree;C;100%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5R)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyl-dihydrofuran-2(3H)-one
1309922-72-2

(3S,5R)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyl-dihydrofuran-2(3H)-one

(2S,4R,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
1607844-94-9

(2S,4R,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With propionic acid at 110℃; for 2h;95%
tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate
866030-35-5

tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate

aminopivalinamide
324763-51-1

aminopivalinamide

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate
173338-07-3

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate

Conditions
ConditionsYield
With 2-Ethylhexanoic acid In n-heptane at 60℃; Reagent/catalyst; Temperature; Solvent; Time;94%
With 2-Ethylhexanoic acid In n-heptane at 60℃; for 40h; Solvent; Reagent/catalyst;93%
With 2-Ethylhexanoic acid In n-heptane at 70℃; for 8h; Inert atmosphere;92%
aminopivalinamide
324763-51-1

aminopivalinamide

1,1-dimethylethyl[(1S,3S)-3-[{4-methoxy-3-(3-methoxypropoxy)phenyl}methyl]-4-methyl-1-[tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamate

1,1-dimethylethyl[(1S,3S)-3-[{4-methoxy-3-(3-methoxypropoxy)phenyl}methyl]-4-methyl-1-[tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamate

C35H61N3O8

C35H61N3O8

Conditions
ConditionsYield
2-Ethylhexanoic acid In tetrahydrofuran at 100℃; for 6h; Product distribution / selectivity;93%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

Conditions
ConditionsYield
With propionic acid at 120℃; for 1.5h;87%
aminopivalinamide
324763-51-1

aminopivalinamide

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester
1236549-00-0

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester
1236549-06-6

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester

Conditions
ConditionsYield
With 2-Ethylhexanoic acid In di-isopropyl ether at 60℃; Solvent; Reagent/catalyst;86%
With 2-Ethylhexanoic acid In di-isopropyl ether at 60℃; Reagent/catalyst; Solvent;86%
With 2-hydroxypyridin; triethylamine In toluene for 16h; Reflux; Inert atmosphere;82%
aminopivalinamide
324763-51-1

aminopivalinamide

C30H49NO7

C30H49NO7

C35H61N3O8

C35H61N3O8

Conditions
ConditionsYield
With 2-Ethylhexanoic acid at 120℃; for 0.833333h;84%
2-hydroxypyridin
142-08-5

2-hydroxypyridin

aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
324763-47-5

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With triethylamine79%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5R)-5-[(1R,3S)-1-azido-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]dihydro-3-isopropyl-2(3H)-furanone

(3S,5R)-5-[(1R,3S)-1-azido-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]dihydro-3-isopropyl-2(3H)-furanone

(2S,4R,5R,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide

(2S,4R,5R,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With triethylamine In toluene at 80 - 90℃; for 20h;78.5%
aminopivalinamide
324763-51-1

aminopivalinamide

N-{(S)-2-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide
1000047-42-6

N-{(S)-2-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

(2S,4S,5S)-6-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-5-(2-nitrobenzenesulfonylamino)hexanoic acid (2-carbamoyl-2-methylpropyl)amide
1000047-43-7

(2S,4S,5S)-6-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-5-(2-nitrobenzenesulfonylamino)hexanoic acid (2-carbamoyl-2-methylpropyl)amide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 15h;78%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
324763-47-5

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃;76%
With 2-hydroxypyridin; triethylamine59%
aminopivalinamide
324763-51-1

aminopivalinamide

N-{(1S)-2-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

N-{(1S)-2-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

(2S,4S,5S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-6-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-5-{[(2-nitrophenyl)sulfonyl]amino}hexanamide

(2S,4S,5S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-6-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-5-{[(2-nitrophenyl)sulfonyl]amino}hexanamide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 2h;73%
methyl 3-amino-2,2-dimethylpropionate
25307-82-8

methyl 3-amino-2,2-dimethylpropionate

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
With ammonia In methanol at 60℃; under 3750.38 Torr; for 48h; Autoclave;100%
2-cyano-2-methylpropanamide
7505-93-3

2-cyano-2-methylpropanamide

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Stage #1: 2-cyano-2-methylpropanamide With ammonia; Raney nickel In methanol at 25 - 35℃; Autoclave;
Stage #2: With hydrogen In methanol at 60 - 65℃; under 5149.01 - 5884.58 Torr; for 10h;
87.5%
With ammonia; hydrogen; Raney nickle In methanol at 60 - 70℃; under 3750.38 Torr; for 10h; Autoclave;78%
Multi-step reaction with 2 steps
1.1: LAH / tetrahydrofuran
1.2: Et3N
2.1: H2 / Pd()OH)2/C
View Scheme
With ammonia; hydrogen; raney nickel In methanol at 40 - 45℃; under 2942.29 Torr; for 14h;
With ammonium hydroxide; 5% rhodium on activated aluminium oxide; hydrogen In ethanol; water under 3102.97 Torr; for 72h;
(2-carbamoyl-2-methylpropyl)carbamic acid benzyl ester
666844-61-7

(2-carbamoyl-2-methylpropyl)carbamic acid benzyl ester

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
With hydrogen; palladium-carbon In ethanol at 20℃; for 2h;85%
With hydrogen; palladium hydroxide - carbon
With hydrogen; palladium 10% on activated carbon In methanol at 20℃; for 2h;
chloro-pivalic acid amide
41461-75-0

chloro-pivalic acid amide

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
With ammonia; sodium methylate In methanol at 60℃; for 50h; Autoclave;62%
Multi-step reaction with 3 steps
1.1: sodium hydroxide / methanol / 70 h / 50 - 53 °C / Sealed tube
1.2: 0.17 h / 0 - 20 °C
2.1: hydrogenchloride / 20 h / 20 °C
3.1: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
α-(nitromethyl)isobutyronitrile
114583-17-4

α-(nitromethyl)isobutyronitrile

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
With methanol; Lindlar's catalyst Hydrogenation;
With nickel Hydrogenation;
With hydrogenchloride; iron
hydrogenchloride
7647-01-0

hydrogenchloride

α-(nitromethyl)isobutyronitrile
114583-17-4

α-(nitromethyl)isobutyronitrile

iron powder

iron powder

A

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide
859065-87-5

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide

B

2,2-Dimethyl-1,3-diaminopropane
7328-91-8

2,2-Dimethyl-1,3-diaminopropane

C

3-amino-2,2-dimethyl-propionitrile
67744-70-1

3-amino-2,2-dimethyl-propionitrile

D

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
at 60 - 70℃;
at 60 - 70℃;
methanol
67-56-1

methanol

α-(nitromethyl)isobutyronitrile
114583-17-4

α-(nitromethyl)isobutyronitrile

palladium-CaCO3

palladium-CaCO3

A

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide
859065-87-5

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide

B

2,2-Dimethyl-1,3-diaminopropane
7328-91-8

2,2-Dimethyl-1,3-diaminopropane

C

3-amino-2,2-dimethyl-propionitrile
67744-70-1

3-amino-2,2-dimethyl-propionitrile

D

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Hydrogenation;
Hydrogenation;
methanol
67-56-1

methanol

α-(nitromethyl)isobutyronitrile
114583-17-4

α-(nitromethyl)isobutyronitrile

Raney nickel

Raney nickel

A

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide
859065-87-5

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide

B

2,2-Dimethyl-1,3-diaminopropane
7328-91-8

2,2-Dimethyl-1,3-diaminopropane

C

3-amino-2,2-dimethyl-propionitrile
67744-70-1

3-amino-2,2-dimethyl-propionitrile

D

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Hydrogenation;
Hydrogenation;
α-(nitromethyl)isobutyronitrile
114583-17-4

α-(nitromethyl)isobutyronitrile

Raney nickel

Raney nickel

methanolic NH3

methanolic NH3

A

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide
859065-87-5

2-(5,5-dimethyl-hexahydro-pyrimidin-2-yl)-2-methyl-propionic acid amide

B

2,2-Dimethyl-1,3-diaminopropane
7328-91-8

2,2-Dimethyl-1,3-diaminopropane

C

3-amino-2,2-dimethyl-propionitrile
67744-70-1

3-amino-2,2-dimethyl-propionitrile

D

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
at 100℃; Hydrogenation;
at 100℃; Hydrogenation;
methyl 2,2-dimethyl-cyanoacetate
72291-30-6

methyl 2,2-dimethyl-cyanoacetate

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Stage #1: methyl 2,2-dimethyl-cyanoacetate With ammonia; hydrogen; nickel In 1-methyl-pyrrolidin-2-one; water at 80℃; under 3750.38 Torr; for 1.5h;
Stage #2: With ammonia; hydrogen; nickel In 1-methyl-pyrrolidin-2-one; water at 80℃; under 150015 Torr; Product distribution / selectivity;
Stage #1: methyl 2,2-dimethyl-cyanoacetate With ammonia; hydrogen; cobalt In water; butan-1-ol at 80℃; under 3750.38 Torr; for 1.5h;
Stage #2: With ammonia; hydrogen; cobalt In water; butan-1-ol at 80℃; under 48754.9 Torr; Product distribution / selectivity;
Stage #1: methyl 2,2-dimethyl-cyanoacetate With ammonia; hydrogen; cobalt In methanol; water at 80℃; under 3750.38 Torr; for 1.5h;
Stage #2: With ammonia; hydrogen; cobalt In methanol; water at 80℃; under 48754.9 Torr; Product distribution / selectivity;
Stage #1: methyl 2,2-dimethyl-cyanoacetate With ammonia; hydrogen; nickel In water; butan-1-ol at 80℃; under 3750.38 Torr; for 1.5h;
Stage #2: With ammonia; hydrogen; nickel In water; butan-1-ol at 80℃; under 48754.9 Torr; Product distribution / selectivity;
methyl 2,2-dimethyl-cyanoacetate
72291-30-6

methyl 2,2-dimethyl-cyanoacetate

A

aminopivalinamide
324763-51-1

aminopivalinamide

B

methyl 3-amino-2,2-dimethylpropionate
25307-82-8

methyl 3-amino-2,2-dimethylpropionate

Conditions
ConditionsYield
With ammonia; hydrogen; mixture of 28percent NiO, 28percent CoO, 13percent CuO, 31percent ZrO2; hydrogenated In methanol at 100℃; under 150015 Torr; Product distribution / selectivity;
With ammonia; hydrogen; mixture of 28percent NiO, 28percent CoO, 13percent CuO, 31percent ZrO2; hydrogenated In tetrahydrofuran at 100℃; under 150015 Torr; Product distribution / selectivity;
4,4-dimethylpyrazolidin-3-one
2941-18-6

4,4-dimethylpyrazolidin-3-one

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
With hydrogen; Raney-Nickel In 2-methyl-propan-1-ol at 55 - 65℃; under 750.075 Torr; Inert atmosphere; Sealed tube;
2-cyano-2-methyl-propionic acid ethyl ester
1572-98-1

2-cyano-2-methyl-propionic acid ethyl ester

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonia / methanol / 12 h / 25 - 30 °C
2: hydrogen; ammonia / raney nickel / methanol / 14 h / 40 - 45 °C / 2942.29 Torr
View Scheme
Multi-step reaction with 2 steps
1.1: ammonia / methanol / 25 - 35 °C
2.1: ammonia / Raney nickel / methanol / 25 - 35 °C / Autoclave
2.2: 10 h / 60 - 65 °C / 5149.01 - 5884.58 Torr
View Scheme
Multi-step reaction with 2 steps
1: ammonia / methanol / 96 h / 35 °C / Sealed tube; Cooling with ice
2: hydrogen; ammonium hydroxide; 5% rhodium on activated aluminium oxide / ethanol; water / 72 h / 3102.97 Torr
View Scheme
3-Hydroxy-2,2-dimethylpropanoic acid
4835-90-9

3-Hydroxy-2,2-dimethylpropanoic acid

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: hydrogen bromide / water / 19 h / 100 °C
2: ammonia / 1,4-dioxane / 16 h / 60 °C / 2250.23 Torr / Autoclave
3: hydrogenchloride / 20 h / 20 °C
4: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
aminopivalic acid
19036-43-2

aminopivalic acid

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrogenchloride / 20 h / 20 °C
2: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
3-Chloropivaloyl chloride
4300-97-4

3-Chloropivaloyl chloride

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonia / dichloromethane / 2.75 h / 20 °C / Cooling with ice
2: sodium methylate; ammonia / methanol / 50 h / 60 °C / Autoclave
View Scheme
Multi-step reaction with 4 steps
1.1: ammonia / dichloromethane / 2.75 h / 20 °C / Cooling with ice
2.1: sodium hydroxide / methanol / 70 h / 50 - 53 °C / Sealed tube
2.2: 0.17 h / 0 - 20 °C
3.1: hydrogenchloride / 20 h / 20 °C
4.1: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
3-bromo-2,2-dimethylpropionic acid
2843-17-6

3-bromo-2,2-dimethylpropionic acid

aminopivalinamide
324763-51-1

aminopivalinamide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ammonia / 1,4-dioxane / 16 h / 60 °C / 2250.23 Torr / Autoclave
2: hydrogenchloride / 20 h / 20 °C
3: ammonia / methanol / 48 h / 60 °C / 3750.38 Torr / Autoclave
View Scheme
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

acetic acid (1S,2S,4S)-2-azido-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester

acetic acid (1S,2S,4S)-2-azido-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 90℃; for 16h; After distillation of a part of Et3N over a period of 0.5 h further 8.5 h heating at 90 °ree;C;100%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5R)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyl-dihydrofuran-2(3H)-one
1309922-72-2

(3S,5R)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyl-dihydrofuran-2(3H)-one

(2S,4R,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
1607844-94-9

(2S,4R,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With propionic acid at 110℃; for 2h;95%
tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate
866030-35-5

tert-butyl {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl}carbamate

aminopivalinamide
324763-51-1

aminopivalinamide

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate
173338-07-3

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate

Conditions
ConditionsYield
With 2-Ethylhexanoic acid In n-heptane at 60℃; Reagent/catalyst; Temperature; Solvent; Time;94%
With 2-Ethylhexanoic acid In n-heptane at 60℃; for 40h; Solvent; Reagent/catalyst;93%
With 2-Ethylhexanoic acid In n-heptane at 70℃; for 8h; Inert atmosphere;92%
aminopivalinamide
324763-51-1

aminopivalinamide

1,1-dimethylethyl[(1S,3S)-3-[{4-methoxy-3-(3-methoxypropoxy)phenyl}methyl]-4-methyl-1-[tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamate

1,1-dimethylethyl[(1S,3S)-3-[{4-methoxy-3-(3-methoxypropoxy)phenyl}methyl]-4-methyl-1-[tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]pentyl]carbamate

C35H61N3O8

C35H61N3O8

Conditions
ConditionsYield
2-Ethylhexanoic acid In tetrahydrofuran at 100℃; for 6h; Product distribution / selectivity;93%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

Conditions
ConditionsYield
With propionic acid at 120℃; for 1.5h;87%
aminopivalinamide
324763-51-1

aminopivalinamide

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester
1236549-00-0

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester
1236549-06-6

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester

Conditions
ConditionsYield
With 2-Ethylhexanoic acid In di-isopropyl ether at 60℃; Solvent; Reagent/catalyst;86%
With 2-Ethylhexanoic acid In di-isopropyl ether at 60℃; Reagent/catalyst; Solvent;86%
With 2-hydroxypyridin; triethylamine In toluene for 16h; Reflux; Inert atmosphere;82%
aminopivalinamide
324763-51-1

aminopivalinamide

C30H49NO7

C30H49NO7

C35H61N3O8

C35H61N3O8

Conditions
ConditionsYield
With 2-Ethylhexanoic acid at 120℃; for 0.833333h;84%
2-hydroxypyridin
142-08-5

2-hydroxypyridin

aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
324763-47-5

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With triethylamine79%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5R)-5-[(1R,3S)-1-azido-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]dihydro-3-isopropyl-2(3H)-furanone

(3S,5R)-5-[(1R,3S)-1-azido-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]dihydro-3-isopropyl-2(3H)-furanone

(2S,4R,5R,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide

(2S,4R,5R,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With triethylamine In toluene at 80 - 90℃; for 20h;78.5%
aminopivalinamide
324763-51-1

aminopivalinamide

N-{(S)-2-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide
1000047-42-6

N-{(S)-2-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

(2S,4S,5S)-6-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-5-(2-nitrobenzenesulfonylamino)hexanoic acid (2-carbamoyl-2-methylpropyl)amide
1000047-43-7

(2S,4S,5S)-6-[2,2-dimethyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]-4-hydroxy-2-isopropyl-5-(2-nitrobenzenesulfonylamino)hexanoic acid (2-carbamoyl-2-methylpropyl)amide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 15h;78%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one
324763-46-4

(3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide
324763-47-5

(2S,4S,5S,7S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-5-azido-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(methoxypropoxy)benzyl)-8-methylnonanamide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃;76%
With 2-hydroxypyridin; triethylamine59%
aminopivalinamide
324763-51-1

aminopivalinamide

N-{(1S)-2-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

N-{(1S)-2-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}-2-nitrobenzenesulfonamide

(2S,4S,5S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-6-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-5-{[(2-nitrophenyl)sulfonyl]amino}hexanamide

(2S,4S,5S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-6-{isopropyl[4-methoxy-3-(3-methoxypropoxy)benzyl]amino}-5-{[(2-nitrophenyl)sulfonyl]amino}hexanamide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 2h;73%
aminopivalinamide
324763-51-1

aminopivalinamide

triethoxymethylbenzene
1663-61-2

triethoxymethylbenzene

5,5-dimethyl-2-phenyl-5,6-dihydropyrimidin-4(3H)-one

5,5-dimethyl-2-phenyl-5,6-dihydropyrimidin-4(3H)-one

Conditions
ConditionsYield
With acetic acid In ethanol at 110℃; for 24h; Inert atmosphere;72%
aminopivalinamide
324763-51-1

aminopivalinamide

C29H49NO6S

C29H49NO6S

(2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide
173334-57-1

(2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide

Conditions
ConditionsYield
With 2-hydroxypyridin; hydrogenchloride; triethylamine In methanol at 80℃;68%
aminopivalinamide
324763-51-1

aminopivalinamide

tert-butyl {(1S)-2-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}carbamate
1000046-88-7

tert-butyl {(1S)-2-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]ethyl}carbamate

tert-butyl {(2S,3S,5S)-5-[(3-amino-2,2-dimethyl-3-oxopropyl)carbamoyl]-1-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-3-hydroxy-6-methylheptan-2-yl}carbamate
1000046-90-1

tert-butyl {(2S,3S,5S)-5-[(3-amino-2,2-dimethyl-3-oxopropyl)carbamoyl]-1-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-3-hydroxy-6-methylheptan-2-yl}carbamate

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 18h;66%
With 2-hydroxypyridin; triethylamine at 80℃; for 18h;66%
aminopivalinamide
324763-51-1

aminopivalinamide

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester
1236549-00-0

{(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester

A

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester
1236549-06-6

(1S,2S,4S)-4-(2-carbamoyl-2-methylpropyl-carbamoyl)-2-hydroxy-1-{(S)-2-[4-methoxy-3-(3-methoxypropoxy)-benzyl]-3-methylbutyl}-5-methylhexyl-carbamic acid benzyl ester

B

C31H51N3O7

C31H51N3O7

Conditions
ConditionsYield
With 2-hydroxypyridin In tert-butyl methyl ether at 65℃;A 66%
B n/a
tert-butyl (1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-((1-(3-methoxypropyl)-1H-indazol-6-yl)methyl)-4-methylpentylcarbamate
953820-47-8

tert-butyl (1S,3S)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-3-((1-(3-methoxypropyl)-1H-indazol-6-yl)methyl)-4-methylpentylcarbamate

aminopivalinamide
324763-51-1

aminopivalinamide

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-((1-(3-methoxypropyl)-1H-indazol-6-yl)methyl)-2,9-dimethyldecan-5-ylcarbamate
953820-48-9

tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-((1-(3-methoxypropyl)-1H-indazol-6-yl)methyl)-2,9-dimethyldecan-5-ylcarbamate

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃;65%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyldihydrofuran-2(3H)-one
325740-70-3

(3S,5S)-5-((1S,3S)-1-azido-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyldihydrofuran-2(3H)-one

(2S,4S,5R,7S)-5-Azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide
325154-31-2

(2S,4S,5R,7S)-5-Azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine59%
aminopivalinamide
324763-51-1

aminopivalinamide

(3S,5S)-5-{(1R,3S)-1-Benzylamino-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-3-isopropyl-dihydro-furan-2-one

(3S,5S)-5-{(1R,3S)-1-Benzylamino-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-3-isopropyl-dihydro-furan-2-one

(2S,4S,5R,7S)-5-Benzylamino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide
361460-41-5

(2S,4S,5R,7S)-5-Benzylamino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 72h;53%
aminopivalinamide
324763-51-1

aminopivalinamide

{(S)-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]-2-[4-(2-methoxymethoxyphenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]ethyl}carbamic acid benzyl ester
1000047-28-8

{(S)-1-[(2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl]-2-[4-(2-methoxymethoxyphenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]ethyl}carbamic acid benzyl ester

{(1S,2S,4S)-4-(2-carbamoyl-2-methylpropylcarbamoyl)-2-hydroxy-1-[4-(2-methoxymethoxyphenyl)-2,2-dimethyl-5-oxopiperazin-1-ylmethyl]-5-methylhexyl}carbamic acid benzyl ester
1000047-29-9

{(1S,2S,4S)-4-(2-carbamoyl-2-methylpropylcarbamoyl)-2-hydroxy-1-[4-(2-methoxymethoxyphenyl)-2,2-dimethyl-5-oxopiperazin-1-ylmethyl]-5-methylhexyl}carbamic acid benzyl ester

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 80℃; for 11h;52%
aminopivalinamide
324763-51-1

aminopivalinamide

Triethyl orthoacetate
78-39-7

Triethyl orthoacetate

2,5,5-trimethyl-5,6-dihydropyrimidin-4(3H)-one

2,5,5-trimethyl-5,6-dihydropyrimidin-4(3H)-one

Conditions
ConditionsYield
With acetic acid In ethanol at 110℃; for 24h; Inert atmosphere;50%
aminopivalinamide
324763-51-1

aminopivalinamide

(2R,2'S,3S,4'S,5S)-3-isopropyl-5-(4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-2-(4-methoxy-3-(3-methoxypropoxy)-phenyl)-pyrrolidine-1-sulfonic acid 2,2,2-trichloro-ethyl ester
1200341-46-3

(2R,2'S,3S,4'S,5S)-3-isopropyl-5-(4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-2-(4-methoxy-3-(3-methoxypropoxy)-phenyl)-pyrrolidine-1-sulfonic acid 2,2,2-trichloro-ethyl ester

(2R,3S,5S)-2,2,2-trichloroethyl 5-((1S,3S)-3-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-1-hydroxy-4-methylpentyl)-3-isopropyl-2-(4-methoxy-3-(3-methoxypropoxy)phenyl)pyrrolidine-1-sulfonate
1219468-79-7

(2R,3S,5S)-2,2,2-trichloroethyl 5-((1S,3S)-3-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-1-hydroxy-4-methylpentyl)-3-isopropyl-2-(4-methoxy-3-(3-methoxypropoxy)phenyl)pyrrolidine-1-sulfonate

Conditions
ConditionsYield
With 2-hydroxypyridin; triethylamine at 85℃; Inert atmosphere;47%
With 2-hydroxypyridin; triethylamine at 85℃; for 72h; Inert atmosphere;
aminopivalinamide
324763-51-1

aminopivalinamide

Triethyl orthopropionate
115-80-0

Triethyl orthopropionate

2-ethyl-5,5-dimethyl-5,6-dihydropyrimidin-4(3H)-one

2-ethyl-5,5-dimethyl-5,6-dihydropyrimidin-4(3H)-one

Conditions
ConditionsYield
With acetic acid In ethanol at 110℃; for 24h; Inert atmosphere;44%
triethyl orthobutyrate
24964-76-9

triethyl orthobutyrate

aminopivalinamide
324763-51-1

aminopivalinamide

5,5-dimethyl-2-propyl-5,6-dihydropyrimidin-4(3H)-one

5,5-dimethyl-2-propyl-5,6-dihydropyrimidin-4(3H)-one

Conditions
ConditionsYield
With acetic acid In ethanol at 110℃; for 24h; Inert atmosphere;36%
aminopivalinamide
324763-51-1

aminopivalinamide

2-{[5-bromo-1-(2-chlorophenyl)-1H-1,2,4-triazol-3-yl]methyl}-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one

2-{[5-bromo-1-(2-chlorophenyl)-1H-1,2,4-triazol-3-yl]methyl}-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one

3-{[1-(2-chlorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-1,2,4-triazol-5-yl]amino}-2,2-dimethylpropanamide

3-{[1-(2-chlorophenyl)-3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1H-1,2,4-triazol-5-yl]amino}-2,2-dimethylpropanamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 180℃; for 5h; Microwave irradiation;29%
aminopivalinamide
324763-51-1

aminopivalinamide

aminopivalic acid
19036-43-2

aminopivalic acid

Conditions
ConditionsYield
With sulfuric acid

324763-51-1Downstream Products

324763-51-1Relevant articles and documents

Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis

Patrick, Donald A.,Gillespie, J. Robert,McQueen, Joshua,Hulverson, Matthew A.,Ranade, Ranae M.,Creason, Sharon A.,Herbst, Zackary M.,Gelb, Michael H.,Buckner, Frederick S.,Tidwell, Richard R.

, p. 957 - 971 (2017/02/19)

A previous publication from this lab (Patrick, et al. Bioorg. Med. Chem. 2016, 24, 2451-2465) explored the antitrypanosomal activities of novel derivatives of 2-(2-benzamido)ethyl-4-phenylthiazole (1), which had been identified as a hit against Trypanosoma brucei, the causative agent of human African trypanosomiasis. While a number of these compounds, particularly the urea analogues, were quite potent, these molecules as a whole exhibited poor metabolic stability. The present work describes the synthesis of 65 new analogues arising from medicinal chemistry optimization at different sites on the molecule. The most promising compounds were the urea derivatives of 2-aryl-benzothiazol-5-amines. One such analogue, (S)-2-(3,4-difluorophenyl)-5-(3-fluoro-N-pyrrolidylamido)benzothiazole (57) was chosen for in vivo efficacy studies based upon in vitro activity, metabolic stability, and brain penetration. This compound attained 5/5 cures in murine models of both early and late stage human African trypanosomiasis, representing a new lead for the development of drugs to combat this neglected disease.

PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES

-

, (2012/03/09)

The present application relates to a process for the preparation of aliskiren and its pharmaceutically acceptable salts. In particular, the present application relates to a process for the preparation of intermediates for aliskiren, and their conversion to aliskiren or its salts.

METHOD FOR THE PREPARATION OF OMEGA-AMINO-ALKANEAMIDES AND OMEGA-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD

-

Page/Page column 18, (2012/02/05)

The present invention relates to method for the preparation of an ω-amino-alkane(thio)amide having the formula (3). Furthermore, novel intermediates and partial reaction steps of the claimed method are disclosed.

PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF

-

, (2011/12/14)

The present invention relates to a process for the preparation of (2S,4S,5S,7S)-N-(2- Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxy propoxy )phenyl]-octanamide compound of formula- 1 and its pharmaceutically acceptable salts thereof. Further, relates to the processes for the preparation of (R)-4-(2-(halomethyl)-3- methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene and (R)-2-(4-methoxy-3-(3-methoxy propoxy) benzyl)-3-methyIbutan-l-ol useful intermediates in the synthesis of compound of formula- 1.

METHOD FOR THE PREPARATION OF W-AMINO-ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD

-

Page/Page column 23, (2011/02/24)

The present invention relates to method for the preparation of an ω-amino-alkane(thio)amide having the general formula (6): Furthermore, novel intermediates and partial reaction steps of the claimed method are disclosed.

A PROCESS FOR DIMETHYLATION OF ACTIVE METHYLENE GROUPS

-

Page/Page column 29, (2010/11/03)

The present invention discloses a process for dimethylation of active methylene groups. Specifically, the invention discloses aprocess for preparing3-amino-2,2- dimethylpropanamide. Compounds produced by the present dimethylation process such as 3-amino-2,2-dimethylpropanamide can be used as intermediates in the route of synthesis of therapeutic, prophylactic or diagnostic agent, for example aliskiren or cryptophycin. Particularly, the invention relates to embodiments further extending to processesfor preparing pharmaceutical dosage form comprising said therapeutic, prophylactic or diagnostic agents. More specifically, the invention relates to the use of compounds produced by the present dimethylation process for the manufacture of therapeutic, prophylactic or diagnostic agents or for the manufacture of pharmaceutical dosage forms comprising said therapeutic, prophylactic or diagnostic agents. The processes according to the present invention can be beneficially applied for the synthesis of various active pharmaceutical ingredients, such as aliskiren or crypthophycin.

CYCLIC AMINE COMPOUND

-

Page/Page column 148-149, (2009/04/23)

The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, -(CH2)a-X1-(CH2)b- (X1: the formula -NH-, -O- or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].

Method for the Production of Aminoalkane Acid Amides

-

Page/Page column 4-5, (2009/01/20)

The invention relates to a process for preparing aminoalkanamides by reacting cyanoalkanoic esters with a) ammonia or an amine and b) hydrogen in the presence of a catalyst, the reaction with component b) being started simultaneously or not later than a maximum of 100 minutes after commencement of the reaction of the cyanoalkanoic ester with component a).

Practical synthesis of an orally active renin inhibitor aliskiren

Dong, Hua,Zhang, Zhi-Liu,Huang, Jia-Hui,Ma, Rujian,Chen, Shu-Hui,Li, Ge

, p. 6337 - 6340 (2007/10/03)

A convergent synthesis of aliskiren was accomplished via the use of Segment AB as the key intermediate, which was prepared via the coupling of the Grignard reagent derived from Segment B with Segment A, followed by subsequent oxidative lactonization.

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

-

Page/Page column 94, (2010/02/12)

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 324763-51-1